back at $4.13 Invocare was recently rated as a Long Term Buy in...

  1. 3,412 Posts.
    back at $4.13 Invocare was recently rated as a Long Term Buy in The Australian newspaper, due to the expected rise in death rate from 130,000 per annum to 150,000 in the years ahead.

    Demography is destiny.

    IVC's business activities might appear morbid to many, but it is an important non discretionary business in society.

    Steady cash flows make this a low risk investment.






 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.